ReShape Lifesciences Inc
NASDAQ:RSLS
ReShape Lifesciences Inc
Total Receivables
ReShape Lifesciences Inc
Total Receivables Peer Comparison
Competitive Total Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ReShape Lifesciences Inc
NASDAQ:RSLS
|
Total Receivables
$1.6m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
Becton Dickinson and Co
NYSE:BDX
|
Total Receivables
$2.6B
|
CAGR 3-Years
7%
|
CAGR 5-Years
2%
|
CAGR 10-Years
9%
|
|
Boston Scientific Corp
NYSE:BSX
|
Total Receivables
$2.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
Stryker Corp
NYSE:SYK
|
Total Receivables
$3.5B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
Abbott Laboratories
NYSE:ABT
|
Total Receivables
$6.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Receivables
$1.1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
16%
|
CAGR 10-Years
17%
|
See Also
What is ReShape Lifesciences Inc's Total Receivables?
Total Receivables
1.6m
USD
Based on the financial report for Mar 31, 2024, ReShape Lifesciences Inc's Total Receivables amounts to 1.6m USD.
What is ReShape Lifesciences Inc's Total Receivables growth rate?
Total Receivables CAGR 5Y
-2%
Over the last year, the Total Receivables growth was -24%. The average annual Total Receivables growth rates for ReShape Lifesciences Inc have been -21% over the past three years , -2% over the past five years .